Tag

Ataibeckley

All articles tagged with #ataibeckley

business2 days ago•10 min saved

Lilly’s $3.8B bet signals a new era for psychedelic mental-health drugs

Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion, signaling Big Pharma’s embrace of psychedelic therapies such as BPL-003 (a synthetic 5-MeO-DMT nasal spray) for treatment-resistant depression, currently in Phase 3 with potential multi-billion-dollar returns. The broader field spans LSD, psilocybin, MDMA, and other compounds, buoyed by positive trial results and regulatory efforts, but faces challenges like insurance coverage and regulatory navigation; several companies eye rapid development under FDA fast-track programs as the psychedelics market aims for widespread clinical use.

via CNBC|

#ataibeckley #business #fda-breakthrough-therapy-designation

business5 days ago•2 min saved

Lilly bets big on psychedelics with $2.8B AtaiBeckley deal

Eli Lilly agreed to acquire AtaiBeckley for $2.8 billion upfront to expand into psychedelic mental-health therapy, led by BPL-003 (intranasal 5-MeO-DMT) which showed phase 2b improvements in treatment-resistant depression; the deal includes up to $1 billion in contingent payments tied to milestones for VLS-01 and BPL-003, plus a $6.75-per-share price with a 40% premium, positioning Lilly to compete with J&J’s Spravato in the TRD market.

via Fierce Biotech|

#acquisition #ataibeckley #business

business5 days ago•13 min saved

Lilly backs psychedelic depression therapy with AtaiBeckley takeover

Eli Lilly plans to acquire AtaiBeckley, the clinical-stage psychedelic drug developer, in a deal valued at about $2.8 billion upfront and up to $3.8 billion with milestones. Lilly will pay $6.75 per ATAI share in cash, a roughly 26% premium to the previous close, and could hand over an additional $2.50 per share if future clinical/regulatory milestones are hit. The move gives Lilly access to AtaiBeckley’s pipeline (including BPL-003 and VLS-01) aimed at treating treatment-resistant depression by promoting synaptic connectivity, a mechanism distinct from conventional antidepressants. The agreement signals Lilly’s expanded focus on neuroscience and psychedelic therapies, as AtaiBeckley’s stock surged in pre-market trading on the news. Regulatory approvals and closing conditions will determine final execution.

via Yahoo Finance|

#ataibeckley #business #depression-treatment